Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
Breast cancer patients who are resistant to neoadjuvant chemotherapy (NeoCT) have a poor prognosis. There is a pressing need to develop in vivo models of chemo resistant tumors to test novel therapeutics. We hypothesized that patient-derived breast cancer xenografts (BCXs) from chemo- naïve and chem...
Main Authors: | Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4556673?pdf=render |
Similar Items
-
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
by: Priscilla F McAuliffe, et al.
Published: (2016-01-01) -
The rapamycin-regulated gene expression signature determines prognosis for breast cancer
by: Tsavachidis Spiridon, et al.
Published: (2009-09-01) -
Whole Genome Sequencing in Cancer Clinics
by: Ken Chen, et al.
Published: (2015-01-01) -
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
by: Yan Xing, et al.
Published: (2019-07-01) -
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
by: Natalia Paez Arango, et al.
Published: (2017-08-01)